Andrew Perry G1 Therapeutics, Inc. (GTHX) insider trading activity

Andrew Perry is Chief Commercial Officer of G1 Therapeutics, Inc.. Currently has a direct ownership of 113,951 shares of GTHX, which is worth approximately $292,854. The most recent transaction as insider was on Jul 01, 2024, when has been sold 35,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 114K

30.82% 3M change

103.68% 12M change

Total Value Held $292,854

Andrew Perry Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 01 2024	BUY Grant, award, or other acquisition	-	35,000 Added 23.5%	113,951 Common Stock
May 13 2024	SELL Open market or private sale	$39,043 $4.79 p/Share	8,151 Reduced 9.36%	78,951 Common Stock
Jan 03 2024	SELL Open market or private sale	$7,528 $3.12 p/Share	2,413 Reduced 2.7%	87,102 Common Stock
Jan 03 2024	BUY Grant, award, or other acquisition	-	33,570 Added 27.27%	89,515 Common Stock
Jul 05 2023	SELL Open market or private sale	$869 $2.45 p/Share	355 Reduced 0.63%	55,945 Common Stock
May 10 2023	BUY Grant, award, or other acquisition	-	35,000 Added 38.34%	56,300 Common Stock
Jan 04 2023	SELL Open market or private sale	$4,575 $5.58 p/Share	820 Reduced 3.71%	21,300 Common Stock

Jan 03 2023	BUY Grant, award, or other acquisition	-	16,100 Added 42.12%	22,120 Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	6,000 Added 49.92%	6,020 Common Stock

Andrew Perry

Chief Commercial Officer

Research Triangle Park, NC

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells GTHX shares.

Notify only if

Value

Insider Trading

Get notified when an G1 Therapeutics, Inc. insider buys or sells GTHX shares.

Notify only if

Operation

Value

Type

News

Receive news related to G1 Therapeutics, Inc.

Track Activities on GTHX

Account